The Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories (IMS-MRL) and its embedded MRC Metabolic Diseases Unit investigate the mechanisms through which metabolic health is maintained and how this is disturbed in disease.
We seek to use that knowledge to aid better treatment and prevention of obesity, Type 2 diabetes and related endocrine and metabolic diseases.
IMS-MRL groups encompass skills in genetics, cell biology, cell signalling, neuroendocrinology, bioenergetics, human and animal physiology, experimental medicine and clinical trials.
The IMS-MRL is the base for the MRC Metabolic Diseases Unit which supports four programmes of research that aim to improve understanding of the mechanisms responsible for obesity and related metabolic diseases.
Together with a Welcome Strategic Award, it also supports core scientific facilities that underpin basic and experimental science at the IMS-MRL.
Latest News
Slowing down fat production could combat harmful inflammation in obesity
Slowing down how quickly the body makes a specific type of fat could help to combat type 2 diabetes, according…
Research from the laboratories of Professor Sue Ozanne and Dr Amanda Sferruzzi-Perri shows that exercise immediately prior to and during…
GIP Receptor is a possible weight-loss target
A receptor for the gut hormone Glucose-dependent insulinotropic polypeptide (GIP) has been shown to be present in several cell types…
Study highlights potential long term health risks associated with treatment for gestational diabetes
New research from IMS-MRL researchers published in PLOS Medicine has found that babies whose mothers received treatment with metformin, a…
